Phase 4 β Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(21 sites)
Japan
Chita Peninsula General Medical Center, Handa, Aichi-ken Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi-ken Nagoya University Hospital, Nagoya, Aichi-ken National Center for Geriatrics and Gerontology, Εbu, Aichi-ken Toyota Kosei Hospital, Toyota, Aichi-ken Ehime University Hospital, TΕon, Ehime Japanese Red Cross Fukuoka Hospital, Fukuoka, Fukuoka Iizuka Hospital, Iizuka, Fukuoka Gunma Prefectural Cardiovascular Center, Maebashi, Gunma Gunma University Hospital, Maebashi, Gunma NHO Takasaki General Medical Center, Takasaki, Gunma Hokkaido Cardiovascular Hospital, Sapporo, Hokkaido Kitasato University Hospital, Sagamihara, Kanagawa Kindai University Hospital, Sakai, Osaka National Cerebral and Cardiovascular Center, Suita, Osaka The University of Osaka Hospital, Suita, Osaka Saitama Medical Center, Kawagoe, Saitama Juntendo University Shizuoka Hospital, Izunokuni, Shizuoka Chutoen General Medical Center, Kakegawa, Shizuoka Osaka General Medical Center, Osaka Juntendo University Hospital, Tokyo